pcDNA™3.1 Directional TOPO™ Expression Kit
Product Image
Invitrogen™

pcDNA™3.1 Directional TOPO™ Expression Kit

pcDNA™3.1 Directional TOPO™ Expression Kitでは、直線化されたトポイソメラーゼI-活性化pcDNA3.1D/V5-HI-TOPO™を使用して、5分間の特定部位クローニングとそれに続く高レベルでの発現を実現します。特定部位クローニングテクノロジーは、以下の理由により発現実験を促進します。•詳細を見る
製品番号(カタログ番号)数量
K49000120反応
K49004040反応
製品番号(カタログ番号) K490001
価格(JPY)
148,800
Each
お問い合わせください ›
数量:
20反応
pcDNA™3.1 Directional TOPO™ Expression Kitでは、直線化されたトポイソメラーゼI-活性化pcDNA3.1D/V5-HI-TOPO™を使用して、5分間の特定部位クローニングとそれに続く高レベルでの発現を実現します。

特定部位クローニングテクノロジーは、以下の理由により発現実験を促進します。

• クローンされた遺伝子のエラーが減少させるために、プルーフリーディング酵素が使用されています
• 90 %を超えるクローンが正しい発現方向にあるため、クローン方向のコロニーのスクリーニングに要する時間が短縮されます

さらに、pcDNA3.1D/V5-His-TOPO™ではCMVプロモーターによる高い発現レベル、オプションの抗V5抗体による組換えタンパク質を簡単に検出するためのC末端V5-His融合タグ、ニッケルキレート樹脂での迅速なタンパク質浄化を実現します。
研究用にのみ使用できます。診断用には使用いただけません。
仕様
構成または誘導システム構造的
供給タイプTransfection
使用対象(アプリケーション)構成的発現
製品タイプTOPO Expression Kit
数量20反応
選択剤(真核生物)Geneticin™(G-418)
ベクターDirectional TOPOベクター、pcDNA
クローニング法Directional TOPO™
製品ラインTOPO、pcDNA, pcDNA
プロモーターCMV
タンパク質タグHisタグ(6x)、V5エピトープタグ, V5 Epitope Tag
Unit SizeEach
組成および保存条件
ボックス1(-20℃で保存):
• 20 µlのpcDNA™3.1D/V5-His-TOPO™(15–20 ng/µl)
• 10 µlのdNTPミックス
• 50 µlの塩溶液
• 1 mlの滅菌水
• 20 µlのT7シーケンシングプライマー(0.1 µg/µl)
• 20 µlのBGH逆シーケンシングプライマー(0.1 µg/µl)
• 10 µlのコントロールPCRテンプレート(0.1 µg/µl)
• 10 µlのコントロールPCRプライマー(0.1 µg/µl each)
• 10 µlの発現プラスミド(0.5 µg/µl)

ボックス2(-80℃で保管):
• 6 mlのS.O.C.培地(4℃または室温で保存可能)
• 21 × 50 µlのTOP10細胞
• 50 µlのpUC19コントロールDNA

よくあるご質問(FAQ)

I performed stable selection but my antibiotic-resistant clones do not express my gene of interest. What could have gone wrong?

Here are possible causes and solutions:

Detection method may not be appropriate or sensitive enough:
- We recommend optimizing the detection protocol or finding more sensitive methods. If the protein is being detected by Coomassie/silver staining, we recommend doing a western blot for increased sensitivity. The presence of endogenous proteins in the lysate may obscure the protein of interest in a Coomassie/silver stain. If available, we recommend using a positive control for the western blot.
- Insufficient number of clones screened: Screen at least 20 clones.
- Inappropriate antibiotic concentration used for stable selection: Make sure the antibiotic kill curve was performed correctly. Since the potency of a given antibiotic depends upon cell type, serum, medium, and culture technique, the dose must be determined each time a stable selection is performed. Even the stable cell lines we offer may be more or less sensitive to the dose we recommend if the medium or serum is significantly different.
- Expression of gene product (even low level) may not be compatible with growth of the cell line: Use an inducible expression system.
- Negative clones may result from preferential linearization at a vector site critical for expression of the gene of interest: Linearize the vector at a site that is not critical for expression, such as within the bacterial resistance marker.

I used a mammalian expression vector but do not get any expression of my protein. Can you help me troubleshoot?

Here are possible causes and solutions:

- Try the control expression that is included in the kit
Possible detection problem:

- Detection of expressed protein may not be possible in a transient transfection, since the transfection efficiency may be too low for detection by methods that assess the entire transfected population. We recommend optimizing the transfection efficiency, doing stable selection, or using methods that permit examination of individual cells. You can also increase the level of expression by changing the promoter or cell type.
- Expression within the cell may be too low for the chosen detection method. We recommend optimizing the detection protocol or finding more sensitive methods. If the protein is being detected by Coomassie/silver staining, we recommend doing a western blot for increased sensitivity. The presence of endogenous proteins in the lysate may obscure the protein of interest in a Coomassie/silver stain. If available, we recommend using a positive control for the western blot. Protein might be degraded or truncated: Check on a Northern. Possible time-course issue: Since the expression of a protein over time will depend upon the nature of the protein, we always recommend doing a time course for expression. A pilot time-course assay will help to determine the optimal window for expression. Possible cloning issues: Verify clones by restriction digestion and/or sequencing.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I am using a mammalian expression vector that has the neomycin resistance gene. Can I use neomycin for stable selection in mammalian cells?

No; neomycin is toxic to mammalian cells. We recommend using Geneticin (a.k.a. G418 Sulfate), as it is a less toxic and very effective alternative for selection in mammalian cells.

Is it okay if my construct has an ATG that is upstream of the ATG in my gene of interest? Will it interfere with translation of my gene?

Translation initiation will occur at the first ATG encountered by the ribosome, although in the absence of a Kozak sequence, initiation will be relatively weak. Any insert downstream would express a fusion protein if it is in frame with this initial ATG, but levels of expressed protein are predicted to be low if there is a non-Kozak consensus sequence. If the vector contains a non-Kozak consensus ATG, we recommend that you clone your gene upstream of that ATG and include a Kozak sequence for optimal expression.

What is the difference between pcDNA3.1 vectors and the pcDNA3.3-TOPO vector?

pcDNA3.1 vectors contain the core CMV promoter that is truncated before the start of transcription, whereas the pcDNA 3.3-TOPO vector has the 672 bp native CMV promoter. This native CMV promoter allows high-level gene expression with two- to five-fold higher protein yields compared to other expression vectors. pcDNA3.1 vectors are available in restriction, TOPO, and Gateway cloning versions and as untagged and epitope-tagged versions, whereas the pcDNA3.3-TOPO vector is a TOPO TA-adapted, untagged vector that can be used to express native proteins without extraneous amino acids, and is hence ideal for antibody production and structural biology.

引用および参考文献 (9)

引用および参考文献
Abstract
RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function.
Authors: Yang Yi; Li Lixin; Wong Guang W; Krilis Steven A; Madhusudhan M S; Sali Andrej; Stevens Richard L;
Journal:J Biol Chem
PubMed ID:11956218
'A cDNA was isolated from interleukin 3-developed, mouse bone marrow-derived mast cells (MCs) that contained an insert (designated mRasGRP4) that had not been identified in any species at the gene, mRNA, or protein level. By using a homology-based cloning approach, the approximately 2.6-kb hRasGRP4 transcript was also isolated from the ... More
Gemin5, a novel WD repeat protein component of the SMN complex that binds Sm proteins.
Authors: Gubitz Amelie K; Mourelatos Zissimos; Abel Linda; Rappsilber Juri; Mann Matthias; Dreyfuss Gideon;
Journal:J Biol Chem
PubMed ID:11714716
'The survival of motor neurons (SMN) protein is the product of the disease gene of spinal muscular atrophy and is found both in the cytoplasm and the nucleus, where it is concentrated in gems. SMN is part of a multi-protein complex that includes Gemin2, Gemin3, and Gemin4. The SMN complex ... More
Subcellular targeting of RGS9-2 is controlled by multiple molecular determinants on its membrane anchor, R7BP.
Authors:Song JH, Waataja JJ, Martemyanov KA,
Journal:J Biol Chem
PubMed ID:16574655
'RGS9-2, a member of the R7 RGS protein family of neuronal RGS (Regulators of G protein Signaling), is a critical regulator of G protein signaling. In striatal neurons, RGS9-2 is tightly associated with a novel palmitoylated protein - R7BP (R7 family Binding Protein). Here we report that R7BP acts to ... More
Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization.
Authors:Wang Q, Griffin H, Southern S, Jackson D, Martin A, McIntosh P, Davy C, Masterson PJ, Walker PA, Laskey P, Omary MB, Doorbar J,
Journal:J Virol
PubMed ID:14694114
'High-risk human papillomaviruses, such as human papillomavirus type 16 (HPV16), are the primary cause of cervical cancer. The HPV16 E1=E4 protein associates with keratin intermediate filaments and causes network collapse when expressed in epithelial cells in vitro. Here, we show that keratin association and network reorganization also occur in vivo ... More
Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs).
Authors: Richter Wito; Conti Marco;
Journal:J Biol Chem
PubMed ID:12177055
'The cAMP-specific PDE4 family consists of four genes, each expressed as several splice variants. These variants are termed long and short forms depending on the presence or absence of two unique N-terminal domains called upstream conserved regions 1 and 2 (UCR1 and 2). UCR1 and UCR2 have been shown to ... More